We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
-11.81%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$5.73B
AUM Growth
+$561M
Cap. Flow
+$883M
Cap. Flow %
15.4%
Top 10 Hldgs %
49.82%
Holding
217
New
75
Increased
44
Reduced
24
Closed
41

Top Buys

Rank Stock Value
1
ORLY icon
O'Reilly Automotive
ORLY
+$93.9M
2
LULU icon
lululemon athletica
LULU
+$73.2M
3
DG icon
Dollar General
DG
+$71.9M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$67.6M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$62.2M

Top Sells

Rank Stock Value
1
HD icon
Home Depot
HD
+$105M
2
BIIB icon
Biogen
BIIB
+$68.7M
3
TGT icon
Target
TGT
+$68.3M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$62.1M
5
OCDX
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
+$62M

Sector Composition

Rank Sector Weight
1 Healthcare 44.4%
2 Miscellaneous 32.07%
3 Consumer Staples 8.91%
4 Consumer Discretionary 7.35%
5 Technology 4.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
State Street SPDR S&P 500 ETF Trust
SPY
$815B
$1.26B 22.05%
+33,500
New +$13.7M
IWM icon
2
iShares Russell 2000 ETF
IWM
$81.2B
$567M 9.9%
+33,500
New +$6.18M
INCY icon
3
Incyte
INCY
$25.7B
$152M 2.65%
2,000,000
+476,000
+31% +$36.1M
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$137M 2.4%
2,048,000
+684,000
+50% +$43.5M
SUPN icon
5
Supernus Pharmaceuticals
SUPN
$2.53B
$136M 2.38%
4,712,000
+1,612,000
+52% +$46.2M
PTCT icon
6
PTC Therapeutics
PTCT
$5.78B
$132M 2.3%
3,296,000
+260,000
+9% +$9.12M
NBIX icon
7
Neurocrine Biosciences
NBIX
$15.8B
$129M 2.25%
1,324,000
+674,000
+104% +$62.2M
TVTX icon
8
Travere Therapeutics
TVTX
$6.15B
$129M 2.25%
5,320,000
+362,000
+7% +$9.1M
REGN icon
9
Regeneron Pharmaceuticals
REGN
$85.2B
$111M 1.94%
188,000
+104,000
+124% +$67.6M
ENTA icon
10
Enanta Pharmaceuticals
ENTA
$410M
$97.8M 1.71%
2,070,000
+946,000
+84% +$51.3M
ORLY icon
11
O'Reilly Automotive
ORLY
$71.1B
$92M 1.6%
+2,183,715
New +$93.9M
BMY icon
12
Bristol-Myers Squibb
BMY
$136B
$89M 1.55%
1,156,000
-240,000
-17% -$18.3M
VRTX icon
13
Vertex Pharmaceuticals
VRTX
$138B
$87.9M 1.53%
312,000
+76,000
+32% +$20.3M
ALKS icon
14
Alkermes
ALKS
$7.73B
$87.1M 1.52%
2,924,000
+1,100,000
+60% +$31.6M
MDGL icon
15
Madrigal Pharmaceuticals
MDGL
$12.5B
$78.7M 1.37%
1,100,000
+122,000
+12% +$8.97M
DG icon
16
Dollar General
DG
$29.4B
$75.6M 1.32%
+308,143
New +$71.9M
MDT icon
17
Medtronic
MDT
$120B
$71.8M 1.25%
800,000
+332,000
+71% +$33.6M
CPRX
18
DELISTED
Catalyst Pharmaceutical
CPRX
$71.5M 1.25%
10,200,000
+1,828,000
+22% +$13.4M
ARGX icon
19
argenx
ARGX
$64.6B
$71.2M 1.24%
188,000
-12,000
-6% -$3.87M
DCPH
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$71M 1.24%
5,400,000
-436,000
-7% -$4.81M
CENTA icon
21
Central Garden & Pet Co Class A
CENTA
$2.26B
$65M 1.13%
2,030,000
+110,000
+6% +$3.62M
ILMN icon
22
Illumina
ILMN
$33B
$62.5M 1.09%
348,492
+165,508
+90% +$42.3M
LULU icon
23
lululemon athletica
LULU
$11.1B
$62.3M 1.09%
+228,573
New +$73.2M
BUD icon
24
AB InBev
BUD
$158B
$61.3M 1.07%
1,136,000
+158,000
+16% +$8.87M
CRSP icon
25
CRISPR Therapeutics
CRSP
$5.39B
$60.8M 1.06%
1,000,000
-24,000
-2% -$1.41M
1
2 3 4 5

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Armistice Capital held 217 positions worth $5.73B, up 11% from $5.17B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Armistice Capital deployed $883M of net new capital in Q2 2022, opening 75 new positions and adding to 44 existing holdings. Its largest new stake was O'Reilly Automotive: 2,183,715 shares worth $92M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 45% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Biogen, an estimated $68.7M trimmed.

  • Armistice Capital's largest Q2 2022 buy was O'Reilly Automotive: 2,183,715 shares worth $92M.
  • Armistice Capital added most to Regeneron Pharmaceuticals in Q2 2022, an estimated $67.6M increase.
  • Armistice Capital's biggest Q2 2022 reduction was Biogen, cutting an estimated $68.7M.
  • Armistice Capital fully exited Home Depot in Q2 2022, selling an estimated $105M.
  • Armistice Capital's ten largest holdings make up 50% of its $5.73B portfolio in Q2 2022.
  • Armistice Capital opened 75 new positions and closed 41 in Q2 2022.
  • Armistice Capital's portfolio value rose 11% quarter-over-quarter to $5.73B.

Based on Armistice Capital's 13F filing for Q2 2022, filed 15 Aug 2022.